TRIPP, a meditation app for Oculus and PlayStation VR which induces psychedelic-like experiences, raises $11M Series A led by Vine Ventures and Mayfield
As an increasing number of startups sell investors on mobile apps that help consumers prioritize well-being and mindfulness …
Context & Ripple Effects
Mindfulness has been a proven venture category since Headspace's 2015 celebrity-backed $30M raise and Calm's $27M Series A, but the money has been drifting toward deeper health claims — Headspace later took $53M in equity plus $40M in debt specifically to build tools for chronic-disease patients.
In parallel, a clinical VR track emerged: Oxford University psychiatry spinout Oxford VR raised £10M to treat mental health with simulations, and its tech already powers Rey's $26M Series A, closed just three months after launch. TRIPP's raise sits at the seam between these two arcs — selling psychedelic-like experiences to consumers while operating community spaces such as Death Q&A, where members process grief, cancer diagnoses, and childhood trauma together.
First-order effects
- Vine Ventures and Mayfield now back a consumer product straddling the two funded categories — audio-first meditation incumbents like Headspace and Calm on one side, clinical VR players like Rey on the other — giving TRIPP capital to deepen its Oculus and PlayStation VR experiences and community offerings.
- TRIPP's grief- and trauma-processing community spaces move the company from entertainment toward territory that clinical VR firms are building regulated products to serve.
Second-order effects
- Headset makers gain a differentiator: a headline wellness experience gives Oculus and PlayStation VR owners a reason to keep hardware in regular use rather than treating it as a games console.
- Audio-app incumbents face a format question — if immersive, psychedelic-like sessions hold users better than guided audio, Headspace and Calm's mobile-first model looks comparatively shallow at the high end of engagement.
Third-order effects
- If consumer 'psychedelic-like' VR keeps absorbing the same use cases clinical VR treats — grief, trauma, anxiety — the boundary between unregulated wellness apps and reimbursable digital therapeutics narrows, and regulators will eventually have to decide which side products like TRIPP sit on.
- The pattern suggests mental-health investment consolidating around two converging tracks — consumer experience platforms and clinically validated tools — with the winners likely being whoever can bridge them first.
The trend: Venture-backed mental wellness is splitting into converging consumer-experience and clinical-VR tracks, with immersive psychedelic-like formats emerging as the contested middle ground.